Published in Cytokine Growth Factor Rev on April 01, 2005
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 4.42
BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A (2007) 4.00
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet (2006) 3.16
Impaired FGF signaling contributes to cleft lip and palate. Proc Natl Acad Sci U S A (2007) 2.94
Niche-mediated control of human embryonic stem cell self-renewal and differentiation. EMBO J (2007) 2.91
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene (2007) 2.83
Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol (2008) 2.71
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest (2008) 2.69
Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 2.67
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med (2010) 2.55
The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol (2009) 2.26
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol (2007) 1.96
Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 1.90
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene (2008) 1.88
Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A (2006) 1.87
The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol (2007) 1.81
Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol (2013) 1.78
FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol (2009) 1.70
The amyloid-beta precursor protein: integrating structure with biological function. EMBO J (2005) 1.68
Current understanding of klotho. Ageing Res Rev (2008) 1.64
FGF signalling: diverse roles during early vertebrate embryogenesis. Development (2010) 1.60
An essential role for FGF receptor signaling in lens development. Semin Cell Dev Biol (2006) 1.58
Hs3st3-modified heparan sulfate controls KIT+ progenitor expansion by regulating 3-O-sulfotransferases. Dev Cell (2014) 1.58
Positive selection for new disease mutations in the human germline: evidence from the heritable cancer syndrome multiple endocrine neoplasia type 2B. PLoS Genet (2012) 1.55
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol (2012) 1.50
FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol (2008) 1.46
Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb (2009) 1.41
Fibroblast growth factor 2 dimer with superagonist in vitro activity improves granulation tissue formation during wound healing. Biomaterials (2015) 1.41
FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One (2011) 1.35
Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci Signal (2009) 1.34
Premature aging in klotho mutant mice: cause or consequence? Ageing Res Rev (2007) 1.29
FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and tissue diffusion. Nat Genet (2009) 1.26
Four independent mutations in the feline fibroblast growth factor 5 gene determine the long-haired phenotype in domestic cats. J Hered (2007) 1.25
Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure (2009) 1.24
Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (2009) 1.22
Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J (2007) 1.22
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol (2010) 1.21
C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem (2008) 1.16
Overview of the FGF23-Klotho axis. Pediatr Nephrol (2009) 1.15
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One (2012) 1.15
FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia (2006) 1.11
Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol (2013) 1.10
The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat (2009) 1.10
A potential link between phosphate and aging--lessons from Klotho-deficient mice. Mech Ageing Dev (2010) 1.10
Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor.fibroblast growth factor receptor complexes. Biochemistry (2009) 1.09
Phosphate toxicity: new insights into an old problem. Clin Sci (Lond) (2011) 1.09
A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest (2009) 1.09
Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol (2011) 1.08
Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res (2010) 1.08
Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem Biol (2013) 1.07
Physical-chemical principles underlying RTK activation, and their implications for human disease. Biochim Biophys Acta (2011) 1.06
Human GnRH deficiency: a unique disease model to unravel the ontogeny of GnRH neurons. Neuroendocrinology (2010) 1.06
Heparan sulfate domain organization and sulfation modulate FGF-induced cell signaling. J Biol Chem (2010) 1.06
Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway. Mol Cell Biol (2007) 1.05
Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci U S A (2010) 1.05
Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform. J Biol Chem (2008) 1.04
Fibronectin induces endothelial cell migration through β1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766. J Biol Chem (2012) 1.04
The FGFRL1 receptor is shed from cell membranes, binds fibroblast growth factors (FGFs), and antagonizes FGF signaling in Xenopus embryos. J Biol Chem (2009) 1.03
Fibroblast growth factor receptor-1 signaling in pancreatic islet beta-cells is modulated by the extracellular matrix. Mol Endocrinol (2007) 1.03
Novel mechanisms of fibroblast growth factor receptor 1 regulation by extracellular matrix protein anosmin-1. J Biol Chem (2009) 1.01
A novel mechanism of sequestering fibroblast growth factor 2 by glypican in lipid rafts, allowing skeletal muscle differentiation. Mol Cell Biol (2010) 1.00
Tyrosine phosphorylation profiling in FGF-2 stimulated human embryonic stem cells. PLoS One (2011) 0.99
Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3. Proc Natl Acad Sci U S A (2007) 0.99
Proteoglycans in prostate cancer. Nat Rev Urol (2012) 0.99
Highly sulfated nonreducing end-derived heparan sulfate domains bind fibroblast growth factor-2 with high affinity and are enriched in biologically active fractions. J Biol Chem (2011) 0.99
The PPARγ-FGF1 axis: an unexpected mediator of adipose tissue homeostasis. Cell Res (2012) 0.99
Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells. Stem Cells (2012) 0.98
Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med (2010) 0.97
Increased protein stability of FGF1 can compensate for its reduced affinity for heparin. J Biol Chem (2009) 0.97
Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol (2012) 0.96
Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem (2012) 0.96
New understandings of the genetic basis of isolated idiopathic central hypogonadism. Asian J Androl (2011) 0.96
Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol (2012) 0.95
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell (2012) 0.95
A genome-wide linkage scan for cleft lip and cleft palate identifies a novel locus on 8p11-23. Am J Med Genet A (2007) 0.94
Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis. PLoS One (2010) 0.94
Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Mol Cell Biol (2009) 0.94
Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies. Structure (2013) 0.93
FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood (2006) 0.93
Phosphorylation and lipid raft association of fibroblast growth factor receptor-2 in oligodendrocytes. Glia (2009) 0.93
GPC5 gene and its related pathways in lung cancer. J Thorac Oncol (2011) 0.92
Mutation in the heparan sulfate biosynthesis enzyme EXT1 influences growth factor signaling and fibroblast interactions with the extracellular matrix. J Biol Chem (2009) 0.92
Temporal and spatial expression of FGF ligands and receptors during Xenopus development. Dev Dyn (2009) 0.92
Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog (2013) 0.91
The physical basis of FGFR3 response to fgf1 and fgf2. Biochemistry (2011) 0.91
Functional overlap between chondroitin and heparan sulfate proteoglycans during VEGF-induced sprouting angiogenesis. Arterioscler Thromb Vasc Biol (2012) 0.91
Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372. Expert Opin Ther Pat (2010) 0.90
A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther (2012) 0.90
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov (2015) 0.90
Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant (2013) 0.89
Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One (2012) 0.89
Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing. Am J Pathol (2011) 0.89
Inhibition of α-SMA by the ectodomain of FGFR2c attenuates lung fibrosis. Mol Med (2012) 0.88
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest (2007) 3.20
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
Current status of surgery in dermatology. J Am Acad Dermatol (2013) 1.98
Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A (2006) 1.87
Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A (2004) 1.70
A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs. Curr Opin Struct Biol (2005) 1.69
Cheek advancement flap with retained standing cone for reconstruction of a defect involving the upper lip, nasal sill, alar insertion, and medial cheek. Dermatol Surg (2012) 1.37
A multistep approach to improving biopsy site identification in dermatology: physician, staff, and patient roles based on a Delphi consensus. JAMA Dermatol (2014) 1.37
Congenital melanocytic nevi: where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis. J Am Acad Dermatol (2012) 1.25
Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res (2009) 1.14
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol (2005) 1.13
Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes. J Am Chem Soc (2010) 0.95
Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Mol Cell Biol (2009) 0.94
Urticarial hypersensitivity reaction caused by temozolomide. J Drugs Dermatol (2010) 0.93
No requirement of trans presentations of IL-15 for human CD8 T cell proliferation. J Immunol (2010) 0.89
Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med (2008) 0.89
Aquagenic wrinkling of the palms: A case report and literature review. Dermatol Online J (2010) 0.86
Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1. J Biol Chem (2011) 0.83
Picosecond laser pulses for tattoo removal: a good, old idea. JAMA Dermatol (2013) 0.81
Multiple facial seborrheic keratosis-like lesions in a young woman with epidermodysplasia verruciformis. Int J Dermatol (2008) 0.79
N-Alkoxyl Templates for Diastereoselective Pyrrolidine Synthesis. Chin Chem Lett (2004) 0.75
The Harvard program and the enduring legacy of Thomas B. Fitzpatrick. J Am Acad Dermatol (2010) 0.75
Re: Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one. Dermatol Surg (2012) 0.75
Who do you prefer? A study of public preferences for health care provider type in performing cutaneous surgery and cosmetic procedures in the United States. Dermatol Surg (2014) 0.75
Chemotherapy-induced inflammatory seborrheic keratoses in a man with acute myeloid leukemia: a variant of Leser-Trélat sign? Cutis (2012) 0.75
Who are the Pioneers? A Critical Analysis of Innovation and Expertise in Cutaneous Noninvasive and Minimally Invasive Cosmetic and Surgical Procedures. Dermatol Surg (2016) 0.75
ASDS Cosmetic Dermatologic Surgery Fellowship Milestones. Dermatol Surg (2016) 0.75
Multi-Center Pilot Study to Evaluate the Safety Pro le of High Energy Fractionated Radiofrequency With Insulated Microneedles to Multiple Levels of the Dermis. J Drugs Dermatol (2016) 0.75
Yellow light gone wild: a tale of permanent laser hair removal with a 595-nm pulsed-dye laser. JAMA Dermatol (2013) 0.75
Postoperative preferences in cutaneous surgery: a patient-centered investigation from an academic dermatologic surgery practice. Dermatol Surg (2013) 0.75
Long-term Comparison of a Large Spot Vacuum Assisted Handpiece vs the Small Spot Size Traditional Handpiece of the 800 nm Diode Laser. J Drugs Dermatol (2017) 0.75
Treatment of Acne Scars With High Intensity Focused Radio Frequency. J Drugs Dermatol (2015) 0.75
The new age of noninvasive facial rejuvenation. Semin Cutan Med Surg (2013) 0.75
Separate- versus same-day preoperative consultation in dermatologic surgery: a patient-centered investigation in an academic practice. Dermatol Surg (2012) 0.75